Similar articles

• Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.

  Demosthenous C, Lalayanni C, Iskas M, Douka V, Pastelli N, Anagnostopoulos A. Demosthenous C, et al. Curr Probl Cancer. 2019 Jun;43(3):222-227. doi: 10.1016/j.currproblcancer.2018.04.006. Epub 2018 May 7. Curr Probl Cancer. 2019. PMID: 29895435
• Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

  Ali S, Moreau A, Melchiorri D, Camarero J, Josephson F, Olimpier O, Bergh J, Karres D, Tzogani K, Gisselbrecht C, Pignatti F. Ali S, et al. Oncologist. 2020 Apr;25(4):e709-e715. doi: 10.1634/theoncologist.2019-0559. Epub 2019 Nov 14. Oncologist. 2020. PMID: 32297447 Free PMC article.
• Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia.

  Elitzur S, Arad-Cohen N, Barzilai-Birenboim S, Ben-Harush M, Bielorai B, Elhasid R, Feuerstein T, Gilad G, Gural A, Kharit M, Litichever N, Nirel R, Weinreb S, Wolach O, Toren A, Izraeli S, Jacoby E. Elitzur S, et al. Pediatr Blood Cancer. 2019 Oct;66(10):e27898. doi: 10.1002/pbc.27898. Epub 2019 Jul 2. Pediatr Blood Cancer. 2019. PMID: 31264788
• A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.

  Halford Z, Coalter C, Gresham V, Brown T. Halford Z, et al. Ann Pharmacother. 2021 Oct;55(10):1236-1253. doi: 10.1177/1060028020988411. Epub 2021 Jan 13. Ann Pharmacother. 2021. PMID: 33435716
• A review of blinatumomab, a novel immunotherapy.

  Newman MJ, Benani DJ. Newman MJ, et al. J Oncol Pharm Pract. 2016 Aug;22(4):639-45. doi: 10.1177/1078155215618770. Epub 2015 Nov 24. J Oncol Pharm Pract. 2016. PMID: 26607163 Review.